Manifold Bio's distinctive technological capability lies in its AI-based in vivo evaluation system. While traditional drug discovery methods primarily involve screening thousands of candidate substances in vitro, Manifold has developed a platform that directly measures the effectiveness of molecular shuttles within living organisms. This allows for the evaluation of thousands of potential BBB crossing pathways, enabling rapid identification of the most effective shuttles. Gleb Kuznetsov, CEO of Manifold, emphasized, "Now, we can enter clinical trials not with our hands tied, but with molecules designed to fully reach the brain." Roche could ultimately pay over $2 billion (approximately 2.76 trillion won) upon achieving milestones, and will also provide royalties to Manifold based on product sales. This agreement represents a strategic move by Roche to transform AI into a core infrastructure for drug development. Roche currently has 21 neuroscience programs in human clinical trials, focusing on developing treatments for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's disease, as well as rare diseases including multiple sclerosis. Last year, Roche's neuroscience product sales reached 9.3 billion Swiss francs (approximately 14 trillion won), accounting for 20% of its total pharmaceutical sales, making it a key business area. Roche has already held a leading position in BBB shuttle technology for over 15 years, developing candidate substances such as the Alzheimer's treatment trontinemab, which utilizes shuttle technology. Through its collaboration with Manifold, Roche aims to prove that AI is not merely an experimental tool, but an innovative engine that will change the paradigm of brain disease treatment.